Gabapentin
گاباپنتین
🧠 Nervous SystemAnticonvulsant / neuropathic pain
Market / country: 🇺🇸 USA
Neurontin (US)
🧮 Dose calculator
Neuropathic pain (diabetic, postherpetic) · Regimen source: FDA Gabapentin · 2.1
- • Day 1: 300 mg once; day 2: 300 twice; day 3: 300 three times; then up to 1,800 mg/day (600 tid). No added benefit shown above 1,800. Displayed dose is from day 3. FDA Gabapentin · 2.1
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Hypersensitivity to gabapentin. FDA Gabapentin · 4
- ⛔ Not established below 3 years. FDA Gabapentin · 8.4
Formulations
- 100 mg capsule — capsule 🇺🇸 USA FDA Neurontin · 3
- 300 mg capsule — capsule 🇺🇸 USA FDA Neurontin · 3
- 400 mg capsule — capsule 🇺🇸 USA FDA Neurontin · 3
- 600 mg tablet (scored) — tablet 🇺🇸 USA FDA Neurontin · 3
- 800 mg tablet (scored) — tablet 🇺🇸 USA FDA Neurontin · 3
- 250 mg/5 mL oral solution — solution 🇺🇸 USA FDA Neurontin · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Gabapentin · 8.1
“Risk Summary The totality of available data from published prospective and retrospective cohort studies pertaining to gabapentin use during pregnancy has not indicated an increased risk of major birth defects or miscarriage.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Gabapentin · 8.2
“Risk Summary Gabapentin is secreted in human milk following oral administration.”
- 👶 ChildrenSafety not established
Label: safety and effectiveness in children have not been established. FDA Gabapentin · 8.4
“Safety and effectiveness of gabapentin in the management of postherpetic neuralgia in pediatric patients have not been established.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Gabapentin · 8.5
“In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.”
- ⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.
🔗 Reference links
- FDA (approval record)ANDA206943
- DailyMed (FDA label)FDA GabapentinFDA Neurontin
- MedlinePlus (NIH)Gabapentin
- WHO ATC/DDDN02BF01
- Darooyab (Iran)Gabapentin
🇮🇷 Registered in Iran Darooyab · G-667/Gabapentin
Dosage forms with Iranian generic codes, per Darooyab.
- 00572 · GABAPENTIN 100MG CAP · کپسول گاباپنتین ۱۰۰ میلیگرم
- 00573 · GABAPENTIN 300MG CAP · کپسول گاباپنتین ۳۰۰ میلیگرم
- 00574 · GABAPENTIN 400MG CAP · کپسول گاباپنتین ۴۰۰ میلیگرم
- 08460 · GABAPENTIN 600MG TAB · قرص گاباپنتین ۶۰۰ میلیگرم
- 08848 · GABAPENTIN 800MG TAB · قرص گاباپنتین ۸۰۰ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Neurontin · 3FDA Gabapentin · 2.1FDA Gabapentin · 2.2FDA Gabapentin · 2.3FDA Gabapentin · 4FDA Gabapentin · 8.4FDA Gabapentin · 8.1FDA Gabapentin · 8.2FDA Gabapentin · 8.5FDA Gabapentin · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-667/Gabapentin
- Clinical review⚠ Unverified